IP Library Granted Patent US 8,030,272
Granted Patent B2
US 8,030,272 · App. 12/403,250 · Granted Oct 4, 2011

Lactoferrin compositions and methods of wound treatment

Assignee: Agennix Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,030,272
App. No.
12/403,250
Granted
Oct 4, 2011
Kind
B2
Abstract

The present invention relates to lactoferrin compositions and methods of using the compositions to treat wounds. The compositions can be administered alone or in combination with other standard wound healing therapies.

Claims (18)

1. A method of treating a skin wound, the method comprising the step of administering a therapeutically effective amount of a lactoferrin composition to a subject having the skin wound to result in an improvement or a remediation of a symptom of the skin wound and wherein the skin wound is selected from the group consisting of a venous stasis ulcer, a pressure ulcer and a diabetic ulcer.

2. The method of claim 1 , wherein said lactoferrin composition is administered topically, orally or parenterally.

3. The method of claim 2 , wherein said lactoferrin composition is administered orally.

4. The method of claim 3 further comprising administering an antacid in conjunction with said lactoferrin composition.

5. The method of claim 2 , wherein said lactoferrin composition is administered topically.

6. The method of claim 2 , wherein said lactoferrin composition is administered parenterally.

7. The method of claim 1 further comprising administering a standard wound healing therapy in combination with the lactoferrin composition.

8. The method of claim 1 , wherein the administering comprises administering said composition for at least one week to twelve weeks.

9. The method of claim 1 , wherein the amount of the lactoferrin that is administered is about 0.0001 microgram to about 100 g per day.

10. The method of claim 1 , wherein said composition is a topical gel, a solution, capsule or a tablet having a lactoferrin concentration of about 0.0001% to about 30%.

11. The method of claim 10 , wherein said topical gel is composed from a polymer selected from the group of consisting of a vinyl polymer, polysaccharide polymer, glycosaminoglycan polymer, protein polymer, polyoxyethylene-polyoxypropylene polymer, carbomers and acrylamide polymer.

12. The method of claim 11 , wherein the polymer concentration is about 0.5% (w/w) to about 3.0% (w/w) and the polymer has a molecular weight of about 50,000 to about 13,000,000.

13. A method of treating a skin wound, the method comprising the step of administering a therapeutically effective amount of a lactoferrin composition to a subject having the skin wound to result in an improvement or a remediation of a symptom of the skin wound, wherein said lactoferrin composition is administered orally or parenterally and wherein the skin wound is selected from the group consisting of a laceration, a penetrating wound, a Staphylococcus aureus infected wound, a venous stasis ulcer, a pressure ulcer, a surgical wound and an open full-thickness skin puncture wound.

14. The method of claim 13 , wherein said lactoferrin composition is administered orally.

15. The method of claim 14 further comprising administering an antacid in conjunction with said lactoferrin composition.

16. The method of claim 13 further comprising administering a standard wound healing therapy in combination with the lactoferrin composition.

17. The method of claim 13 , wherein the administering comprises administering said composition for at least one week to twelve weeks.

18. The method of claim 13 , wherein the amount of the lactoferrin that is administered is about 0.0001 microgram to about 100 g per day.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2011
From: ENGELMAYER, JOSE; VARADHACHARY, ATUL
To: AGENNIX INCORPORATED
Reel/Frame 025723/0603 →
Continuity (3)
Continuation 10663258 · Sep 16, 2003
Provisional Application 60410981 · Sep 16, 2002
Related Publication 20090253627A1 · Oct 8, 2009